7results about "Colony-stimulating factor" patented technology

This invention provides a side-chain coupled compound of a cell-binding molecule having a branched linker and an amanita toxin compound. [Solution] A side-chain conjugated compound of formula (I), TIFF2026097851000286.tif25170 In one embodiment, a side-chain conjugated compound is provided, in which T is a cell-binding agent / molecule, W is a C1-C18 extension unit, and D is an amanita toxin, or an isotope of a chemical element, or a pharmaceutically acceptable salt, hydrate, or hydrated salt; or a polymorphic crystal; or an optical isomer, racemate, diastereomer, or enantiomer thereof.

The invention relates to single chain polypeptides having IL-10 and CSF1 activities and to their use in therapy.

A method for producing professional antigen-presenting cells and professional antigen-presenting cells are provided. [Solution] We provide a method for producing professional antigen-presenting cells, which includes obtaining proliferative myeloid cells (pMCs) by expressing c-MYC or the like in myeloid cells (MCs) differentiated from pluripotent stem cells, and obtaining professional antigen-presenting cells (pAPCs) by expressing GM-CSF and / or M-CSF in the pMCs, as well as human professional antigen-presenting cells produced by this method.

This specification describes immunogenic compositions comprising tumor cells expressing a fusokine containing GM-CSF linked to IL-7 by a peptide linker. Also described are pharmaceutical compositions and methods for treating patients with glioblastoma using tumor cells expressing a fusokine containing GM-CSF linked to IL-7 by a peptide linker.

Genetically engineered progenitor cells and methods of using the same are disclosed herein. Genetically engineered cells differentiated from the genetically engineered progenitor cells of the present disclosure are also disclosed herein. Also disclosed herein is a method of treating a condition in a subject by administering the genetically engineered progenitor cells of the present disclosure or the genetically engineered cells differentiated from the genetically engineered progenitor cells.

The disclosure provides, in various embodiments, non-human animals that comprise a human immune cell engraftment and / or functional human immune system. The disclosure also provides, in various embodiments, methods of generating said non-human animals. The disclosure also provides, in various embodiments, methods of determining immunogenicity of antigens or an immunogenic fragment thereof or antigenic therapies and / or identifying agents that modulate immune response.

The present invention relates to single chain polypeptides having IL-10 activity and CSF1 activity and their use in therapy.